TRDA
Entrada Therapeutics Inc
6.20$
-4.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -3.3% | +8.9% | +13.9% | -4.7% | -5.1% | -7.6% | -7.7% | -8.0% | -8.6% | -11.1% | -10.9% | |
| – | -3.5% | +12.0% | +18.2% | -4.9% | -5.4% | -8.4% | -8.4% | -8.4% | -9.5% | -12.9% | -12.8% | |
| – | +30.3% | +1.2% | +170.7% | -57.9% | +29.7% | -33.0% | +6.8% | +28.7% | -3.1% | -15.4% | +29.9% | |
| – | -0.5% | -7.0% | +43.5% | -4.3% | -6.5% | -8.9% | -7.5% | -7.7% | -9.5% | -13.8% | -12.5% | |
| – | +17.0% | +1,218.7% | -90.1% | -66.1% | +41.4% | -44.5% | -42.3% | +170.8% | -63.2% | +94.3% | -64.3% | |
| – | – | +0.0% | – | – | – | – | – | – | – | – | – | |
| – | -4.8% | +6.5% | -37.0% | -13.1% | -26.1% | -29.1% | +0.1% | +4.2% | -1.3% | -9.2% | +1.2% | |
| – | -4.0% | +9.5% | -50.7% | -17.7% | -44.1% | -53.3% | +7.4% | +21.3% | +1.8% | -21.5% | +11.3% | |
| – | +19.1% | +5.0% | +3.2% | -9.7% | -2.3% | -13.9% | -16.1% | -20.4% | -4.9% | +3.5% | +3.9% | |
| – | +335.8% | -22.9% | -35.3% | -21.0% | +229.6% | -48.6% | -15.1% | +70.5% | -27.7% | +28.0% | +27.8% | |
| – | -1.7% | +11.1% | +59.6% | -1.7% | +1.5% | -2.7% | -9.0% | -10.2% | -10.2% | -11.5% | -13.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -4.0% | +4.3% | +2.1% | +14.4% | +6.0% | -4.6% | +0.6% | +0.3% | -0.2% | +1.1% | +0.9% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.